OCular Therapeutix错过第一季度街景

2026-05-05 19:12

Ocular Therapeutix press release (OCUL): Q1 GAAP EPS of -$0.40 misses by $0.07.
Revenue of $10.8M (+0.9% Y/Y) misses by $1.9M.
Cash balance of $666.7 million as of March 31, 2026, with expected runway into 2028

More on Ocular Therapeutix

Ocular Therapeutix, Inc. (OCUL) Presents at 49th Annual Meeting of the Macula Society - Slideshow
Ocular Therapeutix, Inc. (OCUL) Discusses Phase III SOL-1 Data Highlighting Transformative Durability in Wet AMD Transcript
Ocular Therapeutix, Inc. (OCUL) Discusses Positive Top Line Results From SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD Transcript
Ocular Therapeutix Q1 2026 Earnings Preview
EyePoint sues Ocular over claims related to lead asset